Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Retained Earnings (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Retained Earnings for 4 consecutive years, with -$68.6 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 27.79% to -$68.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$68.6 million through Dec 2025, down 27.79% year-over-year, with the annual reading at -$68.6 million for FY2025, 27.79% down from the prior year.
  • Retained Earnings for Q4 2025 was -$68.6 million at bioAffinity Technologies, down from -$65.4 million in the prior quarter.
  • The five-year high for Retained Earnings was -$35.0 million in Q3 2022, with the low at -$68.6 million in Q4 2025.
  • Average Retained Earnings over 4 years is -$49.1 million, with a median of -$47.6 million recorded in 2024.
  • The sharpest move saw Retained Earnings decreased 20.05% in 2024, then dropped 28.99% in 2025.
  • Over 4 years, Retained Earnings stood at -$36.7 million in 2022, then dropped by 21.65% to -$44.6 million in 2023, then decreased by 20.27% to -$53.6 million in 2024, then dropped by 27.79% to -$68.6 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$68.6 million, -$65.4 million, and -$60.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.